Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant SHR-1210 Plus Apatinib in Acral Melanoma
NCT04331093Phase 2Recruiting
- Start
- Mar 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in acral lentiginous melanoma (ALM). Started Mar 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT04331093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04331093.